Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Colorectal Cancer: early-phase trial registry
154 of 382 indexed Colorectal Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #14 of 28,963 conditions by registered trial count.
382 US clinical trials · 154 currently recruiting · #14 of 28,963 conditions by registered trial count
Colorectal Cancer: 382 US clinical trials tracked, 154 recruiting.
Colorectal Cancer is the subject of 382 registered US clinical trials on ClinicalTrials.gov, 154 of them currently open to new participants. 12 are in Phase 3-4 (later-stage) and 196 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 22 of these trials.
Open enrollment, early-phase tilt
Colorectal Cancer has 382 registered US clinical trials, 154 of them open to new participants right now, about 40% of the total.
- 154
- recruiting participants now
- 40%
- of trials open to enrollment
- 12
- in Phase 3-4 (later-stage)
- 22
- top sponsor: Memorial Sloan Kettering Cancer Center
Corpus placement: #14 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for Colorectal Cancer on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
Colorectal Cancer is recruiting above its size-band peers.
154 of 382 indexed trials (40.3%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Colorectal Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 22 of 382 trials (5.8%). 217 distinct sponsors appear on at least one study for this condition label.
-
Typical Colorectal Cancer enrolment sits around 132 participants.
Median target enrolment is 132 among the 370 trials that report a genuine target (sentinel values excluded). 157 of those (42.4%) plan for fewer than 100 participants.
-
Colorectal Cancer research is mostly interventional.
315 interventional and 67 observational studies make up this index (82.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
382 total, page 6 of 8
Use and Decision-making About Colorectal Cancer Screening Among Hispanic Men and Women
Centers for Disease Control and Prevention
NCT00136227
Promoting Colorectal Cancer Screening in Rural Colorado
Centers for Disease Control and Prevention
NCT00137592
Online Trial Examining Validity of the Shared Decision Making Process Survey With Video Vignettes
Massachusetts General Hospital
NCT04317274
Caring for Those Who Share: Improving the Health of Wisconsin Blood Donors
Medical College of Wisconsin
NCT00772083
Assessing the Effect of a Blood-based Colorectal Cancer Screening Test on Screening Adherence and Colonoscopy Completion
Peter S. Liang, MD MPH
NCT03598166
Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting
Fox Chase Cancer Center
NCT01440855
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Alliance for Clinical Trials in Oncology
NCT00417040
Genetic Trial to Study Diarrhea in Patients With Stage III Colon Cancer Who Are Receiving Chemotherapy
Alliance for Clinical Trials in Oncology
NCT00048971
Redes III Patient Navigator Qol Study
The University of Texas Health Science Center at San Antonio
NCT02275754
Gene Testing in Patients With Colon Cancer
Alliance for Clinical Trials in Oncology
NCT00003571
Study of Flat Polyp Detection Using New Narrow Band Imaging (NBI) Compared to White Light Colonoscopy - The FIND FLAT Colonoscopy Study
VA Palo Alto Health Care System
NCT01310699
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Genentech
NCT01598597
Screening for Familial Colorectal Cancer (CRC) Patients
M.D. Anderson Cancer Center
NCT00632515
Calcium: Magnesium Balance, Microbiota, and Necroptosis and Inflammation
Vanderbilt University Medical Center
NCT04229992
Comparative Effectiveness of CTC & OC
Fox Chase Cancer Center
NCT02143115
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
Esperas Pharma
NCT02632448
Health Behaviors in Patients Who Have Finished Treatment for Stage I, Stage II, or Stage III Colorectal Cancer
Rutgers, The State University of New Jersey
NCT00966667
Colon Cancer Prevention Study
University of North Carolina, Chapel Hill
NCT00924690
Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer
Amgen
NCT00625651
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Dan Zandberg
NCT04157985
Patient-Centered Intervention to Reduce Cancer Patients' Financial Toxicity
Washington University School of Medicine
NCT04314284
Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep
Rush University Medical Center
NCT01695863
S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride
SWOG Cancer Research Network
NCT01416688
Early Post-Op Recovery After Partial Large Bowel Resection
University Hospitals Cleveland Medical Center
NCT00492193
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
Sanofi
NCT05104567
Predicting Local and Distant Recurrence in T1 Colorectal Cancer
City of Hope Medical Center
NCT06314971
Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy
Eastern Cooperative Oncology Group
NCT01079780
Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)
Genentech
NCT01652482
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
Alliance for Clinical Trials in Oncology
NCT00002716
Trial of a Multilevel Intervention to Increase Colorectal Cancer Screening
NYU Langone Health
NCT00836303
A Culturally-adapted Colorectal Cancer Screening Decision Aid Designed for American Indians
UNC Lineberger Comprehensive Cancer Center
NCT03569761
The Deep South Surgical Equity Research Network: Addressing Socioecological Determinants of Health
University of Alabama at Birmingham
NCT05345054
Visceral Lymphatic Mapping Using Isosulfan Blue in Patients With Cancer of the Pancreas, Colon, Stomach, Small Intestine, or Gallbladder
Wake Forest University Health Sciences
NCT00489515
Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin
Dana-Farber Cancer Institute
NCT00831571
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
NuCana
NCT03428958
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery
Alliance for Clinical Trials in Oncology
NCT00316914
Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®)
Cedars-Sinai Medical Center
NCT03723447
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Daiichi Sankyo
NCT00967616
Study to Assess Colonic Microbiota Changes in Response to Energy Drink Consumption
University of Florida
NCT06137248
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
Pfizer
NCT04672460
A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)
SCRI Development Innovations
NCT01490866
Pharmacogenomic Study in Patients of Lung, Colorectal and Head/Neck Cancers Receiving Chemotherapy
University of Kansas Medical Center
NCT00442520
Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)
Bayer
NCT04126733
Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
Hoffmann-La Roche
NCT00022698
5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer
SCRI Development Innovations
NCT00308516
Oral STAT3 Inhibitor, TTI-101, in Patients with Advanced Cancers
Tvardi Therapeutics, Incorporated
NCT03195699
Patients' Opinions and Responses to the National Cancer Institute's Colorectal Cancer Risk Assessment Tool
Indiana University
NCT01803009
Initial Testing of a Mobile App Pain Coping Intervention for Outpatient Oncology Settings (PainPac)
Duke University
NCT05686122
Shared Decision-making and Colorectal Cancer Screening
Abramson Cancer Center at Penn Medicine
NCT04748380
Motivational Interviewing for Colonoscopy
Icahn School of Medicine at Mount Sinai
NCT01877096
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 128 |
| Phase 2 | 68 |
| Phase 3 | 9 |
| Phase 4 | 3 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for Colorectal Cancer right now
154 recruiting of 382 indexed (40% open).
Phase mix: 12 late (III/IV) vs 196 early (I/II) (early-phase heavy).
Top sponsor: Memorial Sloan Kettering Cancer Center (22 trials), 9 others listed. 50 shown below, recruiting first. #14 of 28,963 conditions by registered trial count.
How open-enrollment share is computed
Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.
Frequently Asked Questions
How many clinical trials are there for Colorectal Cancer?
PlainTrial tracks 382 US clinical trials for Colorectal Cancer, of which 154 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Colorectal Cancer?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.